The preliminary revenue range implies accelerating growth — Q3 2026 midpoint of $10.25M would be the highest quarterly revenue in recent history. Monitor the full Q3 2026 earnings release for EPS, margins, and guidance updates to confirm profitability trajectory.
Price Chart
Executive Summary
Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M-$10.4M, representing ~15-18% YoY growth and ~11-14% sequential growth from Q2 2026. The filing is a preliminary revenue pre-announcement only, with no EPS, margins, or guidance details provided. The strong top-line growth signals continued momentum in the thyroid diagnostics franchise.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue expected $10.1M-$10.4M
- YoY growth of ~15-18% vs Q3 2025 revenue of $8.8M
- Sequential growth of ~11-14% vs Q2 2026 revenue of $9.1M
- Preliminary and unaudited — subject to quarter-end closing procedures
- Full Q3 2026 financial results expected at a later date
Financial Impact
Revenue expected $10.1M-$10.4M, up ~15-18% YoY from $8.8M
Risk Factors
- Preliminary and unaudited — actual results may differ materially
- No EPS or margin data provided; profitability trajectory unclear
- Full financial results not yet released
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047090 |
| Exhibit: ex99-1.htm | 0001493152-26-047090 |
| Document: 0001493152-26-047090-index-headers.html | 0001493152-26-047090 |
| Document: 0001493152-26-047090-index.html | 0001493152-26-047090 |
| Document: 0001493152-26-047090.txt | 0001493152-26-047090 |
| 8-K Data (Synthetic) | 0001493152-26-047090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $5.27 $5.40 | ▲ +2.47% | ▲ +3.48% | $5.50 (+4.36%) |
Sep 30, 2026 26d ago | S-1/A | $6.39 $6.00 | ▼ −6.10% | ▼ −7.40% | $5.50 (−13.93%) |
Apr 1, 2026 29w ago | 8-K | $1.96 $2.30 | ▲ +17.47% | ▲ +13.85% | $5.50 (+180.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers